Rani Therapeutics Holdings (RANI)
NASDAQ:RANI
Top Page
Rani Therapeutics Holdings
(NASDAQ:RANI)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.72
▼(-14.64% Downside)
Action:ReiteratedDate:04/02/26
The score is held down primarily by weak financial performance (pre-commercial revenue and persistent losses with ongoing cash burn) and bearish technicals (price below key moving averages with negative MACD). A strengthened 2025 balance sheet (lower debt, higher equity) provides some support, while valuation is difficult to justify on earnings due to losses and no dividend data.
Positive Factors
Balance-sheet improvement
Material reduction in debt and a sharp equity rebound materially improve financial flexibility and lower near-term refinancing risk. This stronger capital structure increases optionality to fund trials, partner deals or withstand delays, supporting operations over the next several quarters.
Negative Factors
Pre-commercial revenue absence
Lack of recurring commercial revenue leaves the business dependent on milestone payments, collaborations or capital markets. This weak revenue visibility means long-term sustainability hinges on successful clinical validation and partner deals, which are binary and time-consuming.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet improvement
Material reduction in debt and a sharp equity rebound materially improve financial flexibility and lower near-term refinancing risk. This stronger capital structure increases optionality to fund trials, partner deals or withstand delays, supporting operations over the next several quarters.
Read all positive factors
Rani Therapeutics Holdings (RANI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$96.18M
Dividend YieldN/A
Average Volume (3M)1.27M
Price to Earnings (P/E)―
Beta (1Y)1.70
Revenue GrowthN/A
EPS Growth25.08%
CountryUS
Employees105
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.07
Shares Outstanding99,721,924
10 Day Avg. Volume1,400,656
30 Day Avg. Volume1,273,637
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.70
Price to Sales (P/S)54.68
P/FCF Ratio-4.75
Enterprise Value/Market Cap0.42
Enterprise Value/Revenue24.74
Enterprise Value/Gross Profit33.00
Enterprise Value/Ebitda-1.08
Forecast
1Y Price Target
$7.00Price Target Upside733.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.24
Revenue Forecast (FY)$9.00M
Rani Therapeutics Holdings Business Overview & Revenue Model
Company Description
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of bi...
How the Company Makes Money
Rani Therapeutics is a clinical-stage company; detailed, consistent commercial revenue sources are not publicly evident from product sales because it does not have widely established marketed products. As a result, the company’s ability to generat...
Rani Therapeutics Holdings Earnings Call Summary
Earnings Call Date:Mar 31, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:May 13, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant advancements in Rani's technology and pipeline, particularly in the obesity treatment market, supported by strategic partnerships and successful preclinical data. However, financial challenges remain, as evidenced by decreased cash reserves and a substantial net loss for the year.Positive Updates
Advancements in RaniPill Technology
The RaniPill technology, designed for oral delivery of biologics, has shown success in preclinical and clinical trials, achieving high bioavailability for 19 molecules and completing three Phase 1 studies with no serious adverse events.
Negative Updates
Decreased Financial Reserves
Cash, cash equivalents, and marketable securities decreased from $48.5 million in 2023 to $27.6 million in 2024, with funding expected to last into Q3 2025.
Read all updates
Q4-2024 Updates
Positive
Negative
Advancements in RaniPill Technology
The RaniPill technology, designed for oral delivery of biologics, has shown success in preclinical and clinical trials, achieving high bioavailability for 19 molecules and completing three Phase 1 studies with no serious adverse events.
Read all positive updates
Company Guidance
During Rani Therapeutics' fourth quarter and full year 2024 earnings call, guidance was provided on the company's strategic focus and financial outlook. The company emphasized advancements in its RaniPill platform, highlighting its application in obesity and immunology spaces. Rani plans to further develop its RT-114 and semaglutide programs, with RT-114 moving into clinical trials by mid-2025. Financially, Rani reported a net loss of $56.6 million for the full year, an improvement from $67.9 million in 2023, partly due to cost containment measures. The company ended the year with $27.6 million in cash and expects this to fund operations into the third quarter of 2025. Additionally, Rani is exploring partnership opportunities to leverage its platform technology across multiple indications.Rani Therapeutics Holdings Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.63M | 1.03M | 0.00 | 0.00 | 2.72M |
| Gross Profit | 733.00K | 1.03M | -822.00K | 0.00 | 2.72M |
| EBITDA | -37.41M | -50.52M | -65.28M | -61.66M | -52.08M |
| Net Income | -29.67M | -30.02M | -33.97M | -30.59M | -8.33M |
Balance Sheet | |||||
| Total Assets | 58.62M | 36.63M | 57.92M | 108.03M | 124.21M |
| Cash, Cash Equivalents and Short-Term Investments | 49.71M | 27.64M | 48.54M | 98.48M | 117.45M |
| Total Debt | 4.32M | 29.71M | 30.10M | 30.21M | 0.00 |
| Total Liabilities | 17.11M | 33.14M | 32.47M | 34.02M | 2.64M |
| Stockholders Equity | 33.01M | 1.99M | 12.87M | 36.85M | 47.41M |
Cash Flow | |||||
| Free Cash Flow | -18.80M | -35.76M | -52.47M | -48.13M | -32.75M |
| Operating Cash Flow | -18.71M | -35.50M | -51.24M | -46.52M | -32.24M |
| Investing Cash Flow | -7.03M | 19.81M | 29.86M | -72.44M | -506.00K |
| Financing Cash Flow | 40.30M | 13.59M | 233.00K | 29.00M | 77.15M |
Rani Therapeutics Holdings Technical Analysis
Negative
0.84
Price Trends
1.15
Negative
1.31
Negative
1.08
Negative
Market Momentum
-0.12
Negative
38.57
Neutral
44.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RANI, the sentiment is Negative. The current price of 0.84 is below the 20-day moving average (MA) of 0.94, below the 50-day MA of 1.15, and below the 200-day MA of 1.08, indicating a bearish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 38.57 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RANI.
Rani Therapeutics Holdings Risk Analysis
Rani Therapeutics Holdings disclosed 102 risk factors in its most recent earnings report. Rani Therapeutics Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Rani Therapeutics Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $83.97M | -2.64 | -291.42% | ― | ― | 61.23% | |
53 Neutral | $249.37M | -9.09 | -51.83% | ― | ― | 92.89% | |
52 Neutral | $108.18M | -0.98 | -55.04% | ― | ― | 44.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $45.08M | ― | -159.43% | ― | ― | 62.84% | |
44 Neutral | $96.18M | -3.01 | -718.54% | ― | ― | 25.08% |
* Healthcare Sector Average
RANI
Rani Therapeutics Holdings
0.84
-0.37
-30.83%
TENX
Tenax Therapeutics
14.78
9.35
172.19%
ANVS
Annovis Bio
1.73
0.51
41.80%
PYPD
PolyPid
4.42
1.72
63.70%
ANTX
AN2 Therapeutics, Inc.
2.98
1.72
136.51%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.